TENAX THERAPEUTICS, INC. Logo

TENAX THERAPEUTICS, INC.

Clinical-stage pharma developing novel therapies for cardiovascular and pulmonary diseases.

TENX | US

Overview

Corporate Details

ISIN(s):
US88032L2097
LEI:
Country:
United States of America
Address:
101 GLEN LENNOX DRIVE, 27517 CHAPEL HILL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tenax Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and pulmonary diseases with high unmet medical needs. The company's lead drug candidate is TNX-103, an oral formulation of levosimendan, which is being advanced through late-stage clinical trials for conditions such as pulmonary hypertension. Tenax's strategy centers on leveraging clinical insights and the established safety profiles of existing compounds to create innovative treatments and de-risk the development pathway.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all TENAX THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TENAX THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TENAX THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America
ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America
IMRN
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO

Talk to a Data Expert

Have a question? We'll get back to you promptly.